Delving into the Latest Updates on LPM6690176 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

LPM6690176

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [4]

Active Indication

RAS mutant Colorectal CancerMetastatic Colorectal CarcinomaAdvanced Malignant Solid Neoplasm+ [6]

Inactive Indication-

Originator Organization

Yantai Chuanghe Biotechnology Co., Ltd

Active Organization

Luye Pharma Group Ltd.Yantai Chuanghe Biotechnology Co., Ltd

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This study is consist of phase 1b (dose escalation + safety run-in) and phase 2 (randomized, controlled). Phase 1b is planned to evaluate the safety and tolerability of LPM6690176 capsule in combination with chemotherapy and Bevacizumab in patients with RAS mutant metastatic colorectal cancer (mCRC), to observe the dose-limiting toxicity (DLT), and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D); Phase 2 is planned to preliminarily evaluate the efficacy of LPM6690176 capsule in combination with chemotherapy + Bev vs. chemotherapy + Bev in patients with previously untreated, RAS mutant mCRC.

Start Date31 Mar 2026

Sponsor / Collaborator

Luye Pharma Group Ltd.

NCT06240546

/ RecruitingPhase 1

A Phase I, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LPM6690176 Capsules in Patients With Advanced Solid Tumors.

This study is a phase 1, first-in-human, open-label, dose-escalation and dose-expansion study designed to evaluate the safety and tolerability, pharmacokinetics characteristics and preliminary anti-tumor activity of LPM6690176 capsules in patients with advanced solid tumors.

Start Date12 Mar 2024

Sponsor / Collaborator

Luye Pharma Group Ltd.

100 Clinical Results associated with LPM6690176

Login to view more data

100 Translational Medicine associated with LPM6690176

Login to view more data

100 Patents (Medical) associated with LPM6690176

Login to view more data

100 Deals associated with LPM6690176

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic Colorectal Carcinoma	Phase 2	China	Luye Pharma Group Ltd.	31 Mar 2026
RAS mutant Colorectal Cancer	Phase 2	China	Yantai Chuanghe Biotechnology Co., Ltd	02 Feb 2026
Advanced Malignant Solid Neoplasm	Phase 1	China	Yantai Chuanghe Biotechnology Co., Ltd	27 Feb 2024
Bile Duct Neoplasms	IND Approval	China	Yantai Chuanghe Biotechnology Co., Ltd	21 Dec 2023
Breast Cancer	IND Approval	China	Yantai Chuanghe Biotechnology Co., Ltd	21 Dec 2023
Lung Cancer	IND Approval	China	Yantai Chuanghe Biotechnology Co., Ltd	21 Dec 2023
Ovarian Cancer	IND Approval	China	Yantai Chuanghe Biotechnology Co., Ltd	21 Dec 2023
Pancreatic Cancer	IND Approval	China	Yantai Chuanghe Biotechnology Co., Ltd	21 Dec 2023
Stomach Cancer	IND Approval	China	Yantai Chuanghe Biotechnology Co., Ltd	21 Dec 2023